Alterity Therapeutics Limited - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of June 2025 for Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate notifications rather than financial performance data.
Material Changes
The primary material event disclosed is the cessation of securities for the ticker symbol "ATH," as detailed in Exhibit 99.1. No other material changes regarding operations or financial position are described in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the notification of the cessation of securities into the company's existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the implications of its cessation.
- Confirm the impact of the cessation on existing Registration Statements (S-8 and F-3).
- Review the full text of Exhibit 99.1 for details on the cessation notification.
- Check for subsequent filings regarding the company's development stage status and capitalization.